Bristol Myers cancer therapy meets main goal in late-stage study
12/10/2026 12:09
Bristol Myers cancer therapy meets main goal in late-stage study Oct 12 (Reuters) - Bristol Myers Squibb BMY.N said on Monday its experimental radiopharmaceutical therapy significantly improved progression-free survival in a late-stage study of patients with advanced rare gastrointestinal and pancreatic tumors whose disease had progressed after prior treatment.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Tasim Zahid)
Recent news on Bristol-Myers Squibb
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Healthcare stocks rally as investors seek safety amid tech debt worries
AstraZeneca strikes $40 million AI drug discovery deal with insitro